EVIDENCE BY CONDITION
A condition is not
a marketing claim.
We examine the exact formulation, population, comparator, outcome, and adverse effects behind medical-cannabis claims. These reviews explain evidence; they do not prescribe treatment.
Cannabis and chronic pain: what the evidence actually measures
Some cannabinoid formulations produce small short-term changes for some pain outcomes, alongside adverse effects and major evidence gaps.
Cannabinoids and chemotherapy nausea: where they fit
Approved cannabinoid medicines exist for treatment-related nausea, but modern guidelines distinguish refractory symptoms from first-line care.
Cannabinoids for multiple-sclerosis spasticity
Evidence and guidance are specific to symptoms, regulated formulations, prior treatment, and continued response.
CBD and epilepsy: one approved medicine, defined syndromes
Randomized trials support purified prescription cannabidiol for specific seizure disorders; that conclusion has precise boundaries.
Cannabis for sleep: small signals, large uncertainty
Studies often involve people with chronic pain rather than primary insomnia, and newer synthesis finds very uncertain clinical benefit.
Cannabis and ADHD: evidence does not support self-treatment
Interest and self-reported use are not the same as clinical evidence; established ADHD guidelines do not recommend cannabis as treatment.
Cannabis, blood pressure, and cardiovascular risk
Acute heart-rate and blood-pressure changes are documented, while longer-term cardiovascular risk estimates remain affected by product and population differences.